Medical Transcription Billing, Corp. (NASDAQ: MTBC) and Fluidigm Corporation (NASDAQ:FLDM) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitabiliy, valuation, institutional ownership, analyst recommendations, risk and dividends.

Insider & Institutional Ownership

9.6% of Medical Transcription Billing, Corp. shares are held by institutional investors. Comparatively, 91.8% of Fluidigm Corporation shares are held by institutional investors. 53.5% of Medical Transcription Billing, Corp. shares are held by company insiders. Comparatively, 4.7% of Fluidigm Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Medical Transcription Billing, Corp. has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Fluidigm Corporation has a beta of 3.46, meaning that its stock price is 246% more volatile than the S&P 500.

Earnings and Valuation

This table compares Medical Transcription Billing, Corp. and Fluidigm Corporation’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Medical Transcription Billing, Corp. $27.60 million 0.44 -$3.02 million ($1.03) -1.17
Fluidigm Corporation $100.98 million 1.08 -$64.73 million ($2.52) -1.48

Medical Transcription Billing, Corp. has higher revenue, but lower earnings than Fluidigm Corporation. Fluidigm Corporation is trading at a lower price-to-earnings ratio than Medical Transcription Billing, Corp., indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medical Transcription Billing, Corp. and Fluidigm Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medical Transcription Billing, Corp. -34.49% -72.93% -23.97%
Fluidigm Corporation -72.60% -94.93% -18.36%

Analyst Recommendations

This is a summary of current recommendations and price targets for Medical Transcription Billing, Corp. and Fluidigm Corporation, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medical Transcription Billing, Corp. 0 0 1 0 3.00
Fluidigm Corporation 0 0 2 0 3.00

Medical Transcription Billing, Corp. currently has a consensus price target of $2.25, indicating a potential upside of 87.50%. Fluidigm Corporation has a consensus price target of $10.50, indicating a potential upside of 182.26%. Given Fluidigm Corporation’s higher probable upside, analysts clearly believe Fluidigm Corporation is more favorable than Medical Transcription Billing, Corp..

Summary

Fluidigm Corporation beats Medical Transcription Billing, Corp. on 7 of the 12 factors compared between the two stocks.

About Medical Transcription Billing, Corp.

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its customers to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services. The Company offers a clearinghouse service, which allows clients to track claim status.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

Receive News & Ratings for Medical Transcription Billing Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing Corp. and related companies with MarketBeat.com's FREE daily email newsletter.